The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It's always fun to find a unique dishware pattern when you're thrifting, but some patterns are extremely rare ... and ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W ...

In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Dianthus Therapeutics is positioned as a category-expanding biotech, leveraging convenience and safety to address autoimmune neuromuscular and rheumatology markets. DNTH boasts a robust balance sheet ...

Develops monoclonal antibody therapeutics, with its lead candidate, DNTH103, targeting severe autoimmune and inflammatory diseases and in phase 1 clinical trials. Operates a clinical-stage ...

Octagon Capital Advisors sold 470,000 shares of Dianthus Therapeutics in the first quarter; the estimated transaction value was $27.22 million (based on quarterly average prices). The quarter-end ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...